List view / Grid view

Squire Patton Boggs



Regulatory Insight: Pharma sector – long a target for antitrust enforcers

30 June 2016 | By ,

Many features of the pharmaceutical sector make it prone to antitrust scrutiny. Intellectual property rights, in particular patents, and the promise of monopoly rents while patents remain valid, play a crucial role in incentivising new product research and development. On the other hand, the European Commission and the various national…